Enhanced innate immunity and killing of respiratory pathogens by nicotinamide in patients with bronchiectasis

Trial Profile

Enhanced innate immunity and killing of respiratory pathogens by nicotinamide in patients with bronchiectasis

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Nicotinamide (Primary)
  • Indications Bacterial infections; Bronchiectasis
  • Focus Biomarker; Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top